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A B S T R A C T
Tobacco kills nearly 6 million people each year, and 90% of the annual 1.59 million lung cancer deaths
worldwide are caused by cigarette smoke. Clinically, a long latency is required for individuals to develop
lung cancer since they were ﬁrst exposed to smoking. In this study, we aimed to identify clinical rele-
vant inﬂammatory factors that are critical for carcinogenesis by treating normal human lung epithelial
cells with tobacco carcinogen nicotine-derived nitrosaminoketone (NNK) for a long period (60 days) and
systematic screening in 84 cytokines/chemokines. We found that a chemokine CCL20 was signiﬁcantly
up-regulated by NNK, and in 78/173 (45.1%) patients the expression of CCL20 was higher in tumor samples
than their adjacent normal lung tissues. Interestingly, CCL20 was up-regulated in 48/92 (52.2%) smoker
and 29/78 (37.2%) nonsmoker patients (p = 0.05), and high CCL20 was associated with poor prognosis.
NNK induced the production of CCL20, which promoted lung cancer cell proliferation and migration. In
addition, an anti-inﬂammation drug, dexamethasone, inhibited NNK-induced CCL20 production and sup-
pressed lung cancer in vitro and in vivo. These results indicate that CCL20 is crucial for tobacco smoke-
caused lung cancer, and anti-CCL20 could be a rational approach to ﬁght against this deadly disease.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Lung cancer is the most common cause of death from cancer
worldwide which accounts for 1.59 million deaths in 2012 [1]
and represents one of the most fatal malignant neoplasms
with a ﬁve year overall survival rate of only 15% for all stages
combined [2]. It is estimated that 90% of the lung cancer deaths
were caused by cigarette smoke [3]. Over 5000 compounds
have been identiﬁed in cigarette smoke, including 73 compounds
which are considered carcinogenic to either laboratory animals
or humans by the International Agency for Research on Cancer.
There are more than 20 compounds that are lung carcinogens,
e.g., polycyclic aromatic hydrocarbons (PAHs) and nicotine-
derived nitrosaminoketone (NNK; or tobacco-speciﬁc nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) [3]. Elucidation
of molecular carcinogenesis of tobacco smoke and derived carcino-
gens is critical to develop successful prevention and treatment
strategies for lung cancer.
Carcinogen NNK induces tumors of the lung in rats, mice, and
hamsters, and plays a major role in lung carcinogenesis [4,5]. It is
a genotoxic carcinogen, converted enzymatically in the body to highly
electrophilic DNA-binding diazohydroxides and related interme-
diates which bind to DNA causingmutations in genes including KRAS
[3]. Recent studies show that tobacco smoke promotes lung tu-
morigenesis by triggering IKKβ- and JNK1-dependent inﬂammation
[6]. Cigarette smoke activates epithelial cells and macrophages and
induces pulmonary inﬂammation and secretion of inﬂammatory
cytokine and chemokine, such as tumor necrosis factor (TNF), trans-
forming growth factor-β (TGF-β), interleukin-1 (IL-1), IL-6, IL-8, CXCL9
and CXCL10 [6–8]. NNK alone induced Akt-dependent prolifera-
tion and NFκB-dependent survival of non-small cell lung cancer cells,
and NFκB is critical to NNK-induced inﬂammation [9]. NNK inhib-
its the production of IL-12, TNF and NO, but stimulates IL-10 and
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PGE2 release [10]. Lipopolysaccharide-elicited chronic lung inﬂam-
mation signiﬁcantly increases the risk of NNK-mediated lung
tumorigenesis [11], and chronic extrinsic lung inﬂammation induced
by NNK in combination with bacteria enhances lung tumorigen-
esis in mice [12]. The chronic inﬂammation may promote neoplasia
by inducing preneoplastic mutation, cell proliferation, resistance to
apoptosis, invasiveness, angiogenesis, and secretion of immune sup-
pressive factors [8]. However, most of the above results were obtained
from cellular and animal models, and studies in smoker patients
are still warranted.
In this study, we used a cytokine/chemokine PCR array to uncover
NNK-induced inﬂammatory factors in normal human lung epithe-
lial 16HBE cells [13], and tested the expression of themost signiﬁcant
factor in 173 lung cancer patients. We also investigated how the
inﬂammatory factor promoted lung cancer progression in vitro and
in vivo. Our results showed that the expression of a chemokine CCL20
was elevated and inversely associated with prognosis in smoker lung




The study was approved by the research ethics committees of all participating
sites. A total of 173 previously untreated non-small cell lung cancers (NSCLCs) were
included (Table 1). Tumor and adjacent normal lung tissues were collected imme-
diately after surgical resection and stored in liquid nitrogen until further use. Serum
samples were obtained from 15 healthy donors and 30 NSCLCs (15 smokers and 15
non-smokers).
Cell culture
The lung adenocarcinoma cell lines A549, NCI-H1975, NCI-H23 and HCC827, large
cell lung cancer line NCI-H460 were obtained from the American Tissue Culture Col-
lection (ATCC, Manassas, VA, USA). Human bronchial epithelial cell line 16HBE [13]
was obtained from Clonetics (Walkersville, MD). Human highly metastatic large-
cell lung cancer line 95D, lung squamous cell carcinoma cell line L78, and lung
adenocarcinoma cell line SPC-A-1 were obtained from the Cell bank of the Chinese
Academy of Sciences (Shanghai). The cells were tested and authenticated by
GoldeneyeTM20A STR method by Beijing Microread Genetics Co., Ltd (Beijing, China)
upon initiation of this study. Cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) or RPMI 1640 (Gibco, California, USA) supplemented with 10% fetal
bovine serum (FBS, Gibco), 100 U/ml penicillin and 100 μg/ml streptomycin [14]. Cell
proliferation was evaluated using MTT assay [15].
PCR array and real-time PCR
RNAwas extracted and transcribed to cDNA by using RT2 First Strand kit (Qiagen,
Valencia, CA). The expression of inﬂammatory factors in 16HBE cells treated
with or without NNK for up to 60 days was determined by Human Inﬂammatory
Cytokines & Receptors RT2 Proﬁler PCR Array containing 84 cytokines/chemokines
and their receptors (Qiagen, Valencia, CA). Real-time PCR was performed using
the SYBR premixExTapTM (Takara, Dalian, China) in CFX96 Real Time System (Bio-
Rad, Hercules, CA) according to the manufacturer’s guidelines and the 2−ΔΔCt method
[16]. Each sample was analyzed in triplicate and repeated 3 times, and the primer
sequences were: GAPDH, forward, 5′-GAAGGTGAAGGTCGGAGTC-3′, reverse,
5′-GAAGATGGTGATGGGATTTC-3′; E-cadherin, forward, 5′-TGCCCAGAAAATGAAAAAGG-
3′, reverse, 5′-GTGTATGTGGCAATGCGTTC-3′; N-cadherin, forward, 5′-ACAGTG
GCCACCTACAAAGG-3′, reverse, 5′-CCGAGATGGGGTTGATAATG-3′; Vimentin, forward,
5′-GAGAACTTTGCCGTTGAAGC-3′; reverse, 5′-GCTTCCTGTAGGTGGCAATC-3′; Snail,
forward, 5′-CCTCCCTGTCAGATGAGGAC-3′, reverse, 5′-CCAGGCTGAGGTATTCCTTG-
3′; CCL20, forward, 5′-GCAAGCAACTTTGACTGCTG-3′, reverse, 5′-ATTTGCG
CACACAGACAACT-3′. For RT-PCR, the primer sequences were: CCL20, forward,
5′-ATGTGCTGTACCAAGAGTT-3′, reverse, 5′-TTTTCAGTTCTTGTACATT-3′; CCR6, forward,
5′-ATGAGCGGGGAATCAATGAAT-3′, reverse, 5′-CGCAGCAGGAAGTGATACACT-3′.
Clonogenic and migration assays
For foci formation, A549 cells were treated with or without CCL20 and seeded
in triplicate onto 35 mm plates (300 cells per plate). After 14 days of culturing, cells
were stained with Giemsa and clones containing more than 50 cells were counted.
Quantitative transmigration assays were performed using an 8.0 μm polycarbon-
ate membrane (Corning, NY, USA) [17]. A549 cells (1 × 104) in DMEM were seeded
in the upper chamber, and different concentrations of CCL20 in DMEM with 0.5%
FCS were added to the lower chamber. After incubation for 24 hours at 37 °C and
5% CO2, the cells on the upper side were removed, and cells on the bottom side were
ﬁxed with methanol for 30 minutes, stained with 0.0005% Gentian Violet Solution
and counted.
Immunohistochemical analysis
Immunohistochemical assay was performed using an anti-CCL20 antibody [18].
Brieﬂy, formalin-ﬁxed, paraﬃn-embedded human or mouse lung cancer tissue speci-
mens (5 μm) were deparaﬃnized by xylene and graded alcohol, and subjected to a
heat-induced epitope retrieval step in citrate buffer solution. The sectionswere blocked
with 5% bovine serum albumin (BSA) for 30 min and incubated with the antibody
at 4 °C overnight, followed by incubation with secondary antibodies for 90 min at
37 °C. Cell smears were ﬁxed by 4% paraformaldehyde, blockedwith 5% BSA for 30min
and incubated with indicated antibodies at 4 °C overnight, followed by H2O2 treat-
ment and incubation with secondary antibodies for 90 min at 37 °C. Detection was
performed with 3,3′-diaminobenzidine (DAB, Zhongshan Golden Bridge Biotech-
nology Co., Ltd, Beijing, China) and counterstained with hematoxylin. The scoring
of immunoreactivity was performed as described [19].
Enzyme-linked immunosorbent assay (ELISA)
Serum concentration of soluble CCL20 was determined using a commercially
available ELISA kit (Shanghai GenePharma, Shanghai, China). The absorbance of the
plates was read at 450 nm using an automated microplate reader (Bio-Tek, Win-
ooski, VT, USA).
Western blot analysis
The cells were seeded in 6-well culture plates, treated with CCL20 and lysed in
RIPA lysis buffer supplemented with the protease inhibitors of cocktail (Sigma, St
Louis, MO), NaF, sodium vanadate, and PMSF. Whole-cell lysates were collected by
centrifugation and quantitated by Coomassie Blue Staining. Lysates containing equal
amounts of protein were separated by SDS-PAGE (8–12%) and transferred onto ni-
trocellulosemembrane (Millipore Corporation, Darmstadt, Germany). After blocking
in 5%non-fatmilk in Tris-buffered saline, themembraneswere incubatedwith certain
primary and then secondary antibodies, and detected by Luminescent Image Ana-
lyzer LSA 4000 (GE, Fairﬁeld, CO, USA). Antibodies used in this studywere: goat anti-
humanCCL20polyclonal antibody, rabbit anti-humanCCR6polyclonal antibody, rabbit
anti-human AKT1/2/3 polyclonal antibody, goat anti-human Lamin B polyclonal
Table 1
Baseline demographic characteristics of the 173 patients whose samples were ana-
lyzed for the expression of CCL20.
Characteristic Case, n CCL20-high, n (%) p* value
Total 173 78 (45.1)
Gender
Male 114 56 (49.1) 0.12
Female 55 20 (36.4)
Unknown 4 2 (50)
Smoking
Smoker 92 48 (52.2) 0.05
Non-smoker 78 29 (37.2)
Unknown 3 1 (33.3)
Age 0.76
<65 115 51 (44.3)
≥65 49 23 (46.9)
Unknown 9 4 (44.4)
Histology
Adenocarcinoma 102 42 (41.2) 0.34**
Squamous-cell carcinoma 55 27 (49.0)
Small cell lung cancer 2 1 (50.0)
Others 8 4 (50.0)
Unknown 6 4 (66.7)
Stage 0.001***
I 68 30 (44.1)
II 24 12 (50.0)
III 46 17 (40.0)
IV 15 10 (66.7)
Unknown 20 9 (45.0)
* Chi-square test.
** Adenocarcinoma versus squamous-cell carcinoma.
*** (I + II + III) versus IV.
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antibody,mouse anti-humanα-tubulinmAb, rabbit anti-humanpAKT1/2/3 polyclonal
antibody (SantaCruzBiotechnology, SantaCruz, CA), rabbit anti-humanERK2polyclonal
antibody (Abcam, Cambridge, MA), rabbit anti-human pERK monoclonal antibody
(CST, Beverly,MA), human CCL20 ELISA Kit (Shanghai GenePharma, Shanghai, China),
rabbit anti-E-Cadherinmonoclonal antibody (CST), andEpithelial–Mesenchymal Tran-
sition (EMT) Antibody Sampler Kit (CST). Nuclear and Cytoplasmic Protein Extraction
Kit (Beyotime,China) and Recombinant Human CCL20 protein (Peprotech, RockyHill,
NJ) were purchased from the indicated vendors, respectively.
siRNA assays
Using HiPerFect Transfection Reagent (Qiagen, Crawley, UK) according to the ma-
nufacturer’s protocol, cells were transfected with 50 nM double-stranded siRNA
oligonucleotides twice. The siRNA sequences were 5′-GAUCAAUGGCUACACAGGA-3′
(NF-κB siRNA1) and 5′-AAGGUGCAGAAAGAGGACA-3′ (NF-κB siRNA2).
Construction of stable knockout cell lines using the CRISPR/Cas-9 system
The experiments were conducted as described [20,21]. The two speciﬁcally tar-
geting sequences for the CCL20 locus are 5′-GCGCAAATCCAAAACAGACT-3′ and
5′-AATATATTGTGCGTCTCCTC-3′, and the identiﬁcation and veriﬁcation of the gene
knockout events were based on sequencing analysis of the genomic PCR fragments
of the target loci.
Animals
Female A/J mice weighing 18–22 g were purchased from the Jackson Laborato-
ry (Bar Harbor, Maine, USA) and fed in a speciﬁc pathogen-free environment and
treated in accordance with the guidelines of the Institutional Animal Use and Care
Committee of our institute. The mice were exposed to NNK (0, 50 mg/kg, twice per
week for 5 weeks) in corn oil via oral gavage and/or dexamethasone (0.5 mg/kg per
day for 12 weeks in diet). For in vivo scans, mice were anesthetized by a mixture
Fig. 1. NNK signiﬁcantly up-regulates CCL20 in normal human lung epithelial cells. (A) A PCR array analysis of the expression of genes encoding cytokines/chemokines in
16HBE cells treated with NNK at 10 or 50 μM for 60 days. (B) Dots represent mean expression of single genes in NNK treated and un-treated cells after normalization to
housekeeping genes (GAPDH, B2M, HPRT1, RPL13A, ACTB). Dotted lines indicate the arbitrary cutoff value of 1.2 fold over- or under-expression in treated versus un-treated
cells. (C) The microarray analysis revealed the expression of 13 genes at mRNA level that showed at least 1.2 times higher or lower in treated than non-treated cells. Red
columns represent genes up-regulated and blue columns down-regulated by NNK treatment.
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of oxygen/isoﬂurane inhalation and positioned with legs fully extended. The entire
lung of each mouse was scanned by a microCT (PerkinElmer, Waltham, MA). When
the mice becamemoribund, they were sacriﬁced, lung tissues were isolated and cells
were harvested for immunohistochemistry or ﬂow cytometry assays.
Statistical analysis
Differences between data groups were evaluated for signiﬁcance using two-
sided Student’s t-test. p values <0.05 were considered statistically signiﬁcant. All
Fig. 2. The expression of CCL20 in lung cancer. (A–C) The expression of CCL20 in lung cancers was evaluated by real-time PCR (A), Western blot (B), and immunohisto-
chemical (IHC) assays (C). N, normal; T, tumor. (D) Serum concentration of CCL20 in samples from healthy donors (HD), smoker (S) or non-smoker (NS) NSCLCs detected by
ELISA.
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experiments were repeated at least three times and the data are presented as
mean ± SD, unless noted otherwise.
Results
NNK induces production of CCL20 in normal human lung epithelial
cells
To mimic the phenomenon that cigarette smoke usually causes
lung cancer after a long latency, normal human lung epithelial 16HBE
cells were treated with NNK at 10 or 50 μM for 60 days, and a real-
time PCR-based microarray was used to explore the cytokines/
chemokines induced by NNK. We found that the expressions of 3
cytokines (IL-5, IL-8, IL-9) and 4 chemokines (CCL20, CCL24, CXCL11,
CXCL12) were signiﬁcantly up-regulated and 2 cytokines (IL-1A, IL-
1B), 3 chemokine/chemokine receptors (CXCL5, CCR3, CCR7) and IL-1
receptor antagonist (IL1RN) were down-regulated by NNK treat-
ment (Fig. 1A–C). Among them, CCL20 was the most signiﬁcantly
elevated gene (Fig. 1A–C). We therefore chose it for further
investigation.
CCL20 is overexpressed in smoker lung cancers
We tested the expression of CCL20 in 173NSCLSs (Table 1), 119 pa-
tients determined by real-time PCR (Fig. 2A) and 54 patients assessed
byWestern blot (Fig. 2B).We found that in 78/173 (45.1%) patients, the
expression of CCL20was higher in tumor samples than their adjacent
normal controls (Table 1). These results were conﬁrmed by immuno-
histochemical assay (Fig. 2C). Moreover, CCL20 was up-regulated in
48/92 (52.2%) smoker and 29/78 (37.2%) nonsmoker patients, and the
expression of CCL20 in smoker patients was higher than in non-
smoker NSCLCs (p = 0.05; Table 1, Fig. 2A–C). By ELISA, we found that
the serumconcentration of CCL20 inNSCLCswas higher than in healthy
donors, while smoker patients had higher CCL20 concentration than
non-smoker NSCLCs (Fig. 2D). These results suggested a potential as-
sociation between tobacco smoke and CCL20 expression.
We analyzed the relationship between CCL20 expression and
tumor stages, and found that patients with relatively earlier disease
(stages I, II, III) had lower CCL20, while those with advanced disease
(stages IV) had higher CCL20 (p = 0.001, Table 1 and Fig. 3A).
Furthermore, in 54 lung cancer patients whose survival informa-
tion was available, the median survival time of CCL20-high patients
(821 days) was much shorter than those with low expression of
CCL20 (1017 days, p = 0.031; Fig. 3B). These results indicate that the
expression of CCL20 is associated with advanced lung cancer and
is inversely associated with clinical outcome.
NNK induces CCL20 production by lung epithelial cells in vitro and
in vivo
We tested whether NNK could induce generation of CCL20 or
not. To do this, normal human lung epithelial 16HBE cells and lung
cancer A549 cells were treated with NNK at 10 and 50 μM for 48 h
or 10 μM for 60 days, and the expression of CCL20 was deter-
mined by real-time PCR. We found that CCL20 was up-regulated by
NNK in a dose- and time-dependent manner (Fig. 4A). In A/J mice
treated by gavage with NNK at 50mg/kg twice per week for 5 weeks,
lung cancer was developed (Fig. 4B, C), and CCL20 was up-regulated
(Fig. 4D). Immunohistochemical analysis showed that CCL20 was
induced by NNK treatment in tumor samples of the mice (Fig. 4B,
E), while serum concentration of CCL20 was also increased as de-
tected by ELISA (Fig. 4F). An anti-inﬂammation drug dexamethasone
(DEX) [22] could reduce NNK-induced tumor burden (Fig. 4B, C) and
prolong the survival of the mice exposed to NNK (Fig. 4G). Inter-
estingly, NNK-induced CCL20 was inhibited by DEX in the mice
(Fig. 4B, D–F).
We investigated how NNKmodulates CCL20 expression. By ana-
lyzing the promoter sequence of CCL20, we identiﬁed three potential
NFκB binding sites (TGGGGAAAACCCC, GGGAAAACCCC, and
AGGGAAATTCC), nine C/EBPα binding sites, and two Hlf binding sites.
NNK is shown to be able to activate NFκB [23,24], and CCL20 is a
target gene of NFκB [25], therefore NNK might up-regulate CCL20
via NFκB pathway. To test this possibility, 16HBE and A549 cells were
treated with NNK in the absence or presence of NFκB inhibitor
BAY11-7082 [26] or NFκB-speciﬁc siRNA, and the expression of CCL20
was assessed. We found that while NNK increased CCL20, BAY11-
7082 and siNFκB signiﬁcantly inhibited this effect (Fig. 4H–J),
suggesting the role for NFκB to play in NNK-induced up-regulation
of CCL20.
The expression of CCL20 receptor CCR6 in lung cancer
The function of CCL20 is mediated by binding to the G-protein
coupled 7-transmembrane receptor CCR6, which is expressed by
most B cells and subsets of T cells and dendritic cells (DCs) [27].
By RT-PCR and immunoﬂuorescence analysis, we found that CCR6
was expressed in normal lung epithelial cells and lung cancer cell
lines (Fig. 5A, B). By real-time PCR, we showed that the expression
of CCR6 in lung cancer tumor samples was approximately equal to
that in their adjacent normal lung tissues (Fig. 5C). By immunohis-
tochemical assay, we conﬁrmed that CCR6 was expressed in tumor
samples of NSCLCs and NNK-treated A/J mice (Fig. 5D).
Fig. 3. The expression of CCL20 is related to advanced disease and poor prognosis. (A) Relationship between the expression of CCL20 and tumor stages of lung cancer pa-
tients. (B) Overall survival of 54 NSCLC patients.
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Fig. 4. NNK induces secretion of CCL20 in vitro and in vivo. (A) NNK up-regulated CCL20 at mRNA level in a time- and dose-dependent manner in 16HBE and A549 cells.
The cells were treated with NNK, and the expression of CCL20 was detected by real-time PCR. (B) The A/J mice treated with NNK and/or dexamethasone were detected by
microCT, and when they became moribund the mice were sacriﬁced. The images of the lung, HE staining, and immunohistochemical analysis of CCL20 are shown. (C) Tumor
volume of the mice treated with NNK and/or dexamethasone. (D) The expression of CCL20 in the lung tissue of mice treated with NNK and/or dexamethasone. (E) The im-
munoreactivity score of lung tissues analyzed by immunohistochemical assay in (B). (F) Serum concentration of CCL20 in mice treated with NNK and/or dexamethasone.
(G) The survival curve of the mice treated with BaP and/or DEX (n = 8 for each group). (H) The expression of CCL20 in cells treated with NNK and/or NFκB inhibitor BAY11-
7082. (I, J) The cells were transfected with NFκB-speciﬁc or negative control siRNA, treated with or without NNK, and the expression of CCL20 was tested by real-time PCR.
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CCL20 secreted by lung epithelial cells is critical to cancer cell
proliferation and migration
CCL20 is expressed by immune cells including macrophages,
T-cells and B-cells [28]. To address whether these cells were other
sources of CCL20 and were involved in NNK-induced lung cancer,
lung tissue samples were harvested from mice treated with NNK
or vehicle. By analyzing cell surface markers in the tumor microen-
vironment using ﬂow cytometry and antibodies against CD45, CD4,
CD19 and CD68, we tested which cell types were increased in NNK-
induced lung cancer. The results showed that as compared to those
in mice treated with vehicle control, CD68+ macrophages, CD4+ T
cells or CD19+ B cells were not signiﬁcantly increased in mice upon
NNK (Fig. 6A). By immunohistochemistry assay of human NSCLC
tumor samples, we showed that while the expression of CCL20 was
high in cancer cells (Fig. 6B), CD68+ macrophages were few (mean,
2.7%). These results suggested that macrophages, T and B cells were
not the main source of elevated CCL20 in tobacco smoke-induced
lung cancer.
We then tested the role that CCL20 plays in lung cancer cell pro-
liferation by knockdown of its expression using CRISPR/Cas-9 system
[20] in A549 cells (Fig. 6C), and found that the clonogenic activity
of the cells was inhibited (Fig. 6D, E), and the proliferation of the
cells (assessed by cell counting) was suppressed (Fig. 6F). In a
transwell assay, we found that knockdown of CCL20 also inhibited
migration of A549 cells (Fig. 6G).
CCL20 promotes proliferation and metastasis of lung cancer
By clonogenic assay, we found that addition of CCL20 to A549
cells signiﬁcantly increased the colony forming activity of the cells
(Fig. 7A). MTT assay demonstrated that CCL20 promoted cell pro-
liferationwhich could be inhibited by an anti-CCR6 antibody (Fig. 7B).
We showed that in A549 and H460 cells, CCL20 up-regulated p-Erk
and p-Akt in a dose-dependent manner (Fig. 7C); in tumor samples
of NNK-treated A/J mice, the expression of p-Erk and p-Akt was up-
regulated, while DEX attenuated this effect (Fig. 7D). CCL20 is a target
gene of STAT3 [29], and NNK was shown to be able to activate this
transcription factor [30]. We showed that in tumor samples of NNK-
treated A/J mice, the expression of p-Stat3 but not total Stat3 was
also up-regulated, while DEX attenuated this effect (Fig. 7D).
CCL20 can promote hepatocellular carcinoma cell proliferation
andmigration by inducing epithelial–mesenchymal transition (EMT)-
like changes via PI3K/AKT and Wnt/β-catenin pathways [31]. We
tested the effects of CCL20 on lung cancer cell migration by a
transwell migration assay, and showed that CCL20 induced migra-
tion of A549 cells, while anti-CCR6 antibody and β-Catenin inhibitor
ICG-001 [32] partially inhibited this effect (Fig. 7E). In A549 and H460
cells, CCL20 increased nuclear β-Catenin (Fig. 7F) and down-
regulated the expression E-Cadherin and up-regulation of Vimentin
(Fig. 7G). By real-time PCR experiments, we found that CCL20 induced
down-regulation of E-Cadherin and up-regulation of N-Cadherin,
Vimentin and Snail at mRNA level, while ICG-001 reversed these phe-
nomena (Fig. 7H). Up-regulation of β-Catenin (in the nucleus) and
Vimentin and down-regulation of E-Cadherin were also seen in A/J
mice treated with NNK (Fig. 7I, J).
Discussion
Tobacco kills nearly 6 million people each year (up to half of its
users), and the annual death toll could rise tomore than eightmillion
by 2030 unless urgent action is taken [33,34]. Comprehensive data
have illustrated pathways of cancer induction, involving carcino-
gen exposure, metabolic activation, DNA adduct formation, and
consequent mutation of critical genes along with the exacerbat-
ing inﬂuences of inﬂammation, cocarcinogenesis, and tumor
promotion [3]. However, many of the studies were conducted in cel-
lular and animal models, and more research using human samples
Fig. 5. CCR6 is expressed on lung cancer cells. (A) The expression of CCL20 and CCR6 in lung cancer cell lines detected by RT-PCR. (B) Immunoﬂuorescence analysis of A549
and H460 cells using an anti-CCR6 antibody and DAPI to counterstain nucleus. (C) The expression of CCR6 in tumor samples and counterpart normal lung tissues of the
patients. (D) Immunohistochemical analysis of CCL20 in tumor samples and their adjacent normal lung tissues.
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is needed to identify biomarkers to screen for those most prone to
develop lung cancer, and to uncover targets for development of ther-
apeutic and chemopreventive approaches.
The key carcinogens of tobacco smoke are NNK and PAHs [3,35].
These carcinogens induce chronic inﬂammation to facilitate carci-
nogenesis. For example, NNK stimulates IL-10 and PGE2 release [10],
PAHs induce secretion of CCL1, CXCL1, CXCL5, TNF-α, IL-1β, IL-6 and
IL-8 [36–39]. On the other hand, a long latency (a hypothesized 10-
year period at least) is required for the development of clinical
recognition of lung cancer since the individuals have been exposed
to cigarette smoke [40]. In this study, we screened for NNK-
induced inﬂammatory factors by using normal human lung epithelial
Fig. 6. CCL20 secreted by lung epithelial cells is critical to cancer cell proliferation and migration. (A) Macrophages, T and B cells in lung tissue samples of mice treated
with vehicle control or NNK. (B) Immunohistochemistry assay of tissue samples of NSCLCs using anti-CCL20 and CD68 antibodies. (C–G) Effects of CCL20 silencing in lung
cancer cells. The expression CCL20 was silenced by CRISPR/Cas-9 system in A549 cells (evaluated by sequencing the genomic fragments of the target loci) (C), and the clonogenic
activity assay (D, E), cell counting (F), and transwell assay were performed.
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Fig. 7. CCL20 promotes lung cancer cell proliferation and migration. (A) Soft agar assay of A549 cells treated with or without CCL20. (B) The growth curve of A549 cells treated with CCL20 and/or anti-CCR6 antibody. (C) Western
blot assays using lysates of cells treated with CCL20 and indicated antibodies. (D) Western blot assays using lysates of lung samples harvested from mice treated with NNK/DEX and indicated antibodies. (E) Transwell assay
using A549 cells co-incubated with CCL20, β-catenin inhibitor ICG001, and anti-CCR6 antibody. (F) Western blot assays using cytoplasmic and nuclear fractions of cells treated with CCL20 and indicated antibodies. (G) Western
blot assays using lysates of cells treated with CCL20/ICG-001 and indicated antibodies. (H) The expression of the indicated genes in cells treated with CCL20/ICG-001 detected by real-time PCR. (I) Western blot assays using
cytoplasmic and nuclear fractions of lung samples harvested from mice treated with NNK and/or DEX and indicated antibodies. (J) Western blot assays using lysates of lung samples harvested from mice treated with NNK











cells exposed to NNK for a long period (60 days) to reﬂect the long
latency of smoker patients to develop lung cancer. We used a
microarray containing 84 known cytokines/chemokines to system-
atically identify abnormalities in chronic inﬂammatory pathway
critical to lung cancer pathogenesis. We found that in cellular and
animal models, NNK induced the secretion of CCL20 (Fig. 4); in pa-
tients with lung cancer, CCL20 was elevated in tumor samples
compared to their adjacent normal lung tissues, and higher ex-
pression of CCL20 was associated with advanced disease and poorer
prognosis (Figs. 2 and 3). Knockdown of CCL20 in lung cancer cells
led to inhibition of cell proliferation and migration (Fig. 6). These
results demonstrate that CCL20 is a critical inﬂammation factor
induced by NNK to facilitate cigarette smoke-caused lung cancer,
and may represent a potential therapeutic target.
CCL20 belongs to the CC chemokine which is responsible for the
chemoattraction of immature dendritic cells, effector/memory T-cells
and B-cells [27]. CCL20 is the only ligand that activates CCR6. CCL20
and CCR6 are overexpressed and associated with poor prognosis in
colorectal cancer [41]. CCL20/CCR6 enhances proliferation of some
types of cancerous cells and promotes metastasis and invasion
[42–45]. Airway epithelial cells release CCL20 in response to
cytokines and PAHs-containing ambient particulate matter [46], and
in patients with chronic obstructive pulmonary disease (COPD) the
expressions of CCL20 mRNA in total lung and CCL20 protein in
sputum are signiﬁcantly higher compared to never-smoker COPD
and smokers without COPD [47]. We showed that the expressions
of CCL20 at both mRNA and protein levels were increased in lung
cancer tumor samples compared to their adjacent normal lung
tissues (Figs. 2 and 5), and smoker patients had higher CCL20 than
non-smoker patients (Table 1, Fig. 2). Together, the above results in-
dicated that CCL20 and CCR6 are critical to tumorigenesis of some
subtypes of cancers, and cigarette smoke or second hand smokemay
be responsible for up-regulation of the chemokine.
Previous study showed that transcription factor β-catenin is crit-
ical for EMT phenotype [48]. We found that CCL20 promoted lung
cancer cell migration and induced EMT-like phenotype in vitro and
in vivo (Fig. 7). We further showed that CCL20 activated β-catenin
by inducing its translocation to the nucleus (Fig. 7). CCL20 is shown
to be able to activate EGFR [42,49], and the activated EGFR induces
β-catenin dissociation from E-cadherin, translocation to the nucleus,
and increased transactivation by GSK-3β-independent mecha-
nisms [50]. EGFR activation also results in the disruption of the
β-catenin/α-catenin complex, thereby abrogating the inhibitory effect
of α-catenin on β-catenin transactivation [51]. In addition, EGFR ac-
tivation induces translocation of PKM2 into the nucleus, where K433
of PKM2 binds to c-Src-phosphorylated Y333 of β-catenin [52].
Therefore, CCL20 may activate β-catenin via the EGFR and its down-
stream signal molecules.
Chemokines have become rational drug targets [53]. We showed
that a wide spectrum anti-inﬂammation agent dexamethasone [54]
inhibited the production of CCL20 by epithelial cells (Fig. 4), inhib-
ited EMT (Fig. 7), reduced tumor burden and prolonged the life span
of the mice (Fig. 4), unveiling a new mechanism of this old drug.
Since dexamethasone is a wide-spectrum anti-inﬂammatory drug
which may cause severe side effects, more speciﬁc, CCL20-targeting
antibodies or small molecules should be developed to combat lung
cancer.
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